Business ❯ Pharmaceutical Industry ❯ Drug Development

Market Competition

Eli Lilly Novo Nordisk Pricing Strategies Sales Performance Consumer Health Weight Loss Products Stock Performance Obesity Drugs Insurance Coverage Insurance Policies Sales Projections Regulatory Compliance Obesity Drug Market Novo Nordisk's Market Position Cost Reduction Alternative Products Generic Drugs Eli Lilly vs Novo Nordisk

Lilly’s Daily Obesity Pill Sustains Weight Loss After Switch From Wegovy or Zepbound

FDA could issue a U.S. decision by March 28 under a faster review timeline, according to Reuters.

FDA Approves Palsonify, First Once-Daily Oral Treatment for Acromegaly

FDA Approves J&J’s Inlexzo Bladder Drug-Delivery Device for BCG‑Unresponsive NMIBC

Eli Lilly’s Oral GLP-1 Pill Matches Injectables in Weight and Blood Sugar Control